Siteman Cancer Center at Washington University St. Louis Offers Novel Personalized Cell Therapy for Melanoma Patients Just Approved by FDA

Where can patients access the first cell therapy targeting melanoma? With the green light from the Food and Drug Administration&nbsp;(FDA), one prestigious Midwestern center with delivery capability is Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. Importantly Washington University doctors and researchers were involved in clinical trials that led to the FDA approval.
At Washington University St. Louis (WUSTL) physicians at Siteman Cancer Center will administer tumor-infiltrating lymphocyte (TIL) therapy to treat certain adult patients with metastatic melanoma, an aggressive skin cancer that has spread to other parts of the body.